Get the Stockscreener App
1.61
1.90%
0.03
Pre-market:
1.63
0.02
+1.24%
Pliant Therapeutics Inc stock is traded at $1.61, with a volume of 1.00M.
It is up +1.90% in the last 24 hours and down -9.55% over the past month.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
See More
Previous Close:
$1.58
Open:
$1.6
24h Volume:
1.00M
Relative Volume:
1.31
Market Cap:
$98.93M
Revenue:
$5.03M
Net Income/Loss:
$-185.41M
P/E Ratio:
-0.521
EPS:
-3.09
Net Cash Flow:
$-139.79M
1W Performance:
+3.87%
1M Performance:
-9.55%
6M Performance:
+19.26%
1Y Performance:
-88.10%
1-Day Range:
$1.58
$1.63
1-Week Range:
$1.53
$1.63
52-Week Range:
$1.1001
$15.80
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Name
Pliant Therapeutics Inc
Sector
Industry
Phone
650-481-6770
Address
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare PLRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.61 | 97.09M | 5.03M | -185.41M | -139.79M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-04-25 | Resumed | Cantor Fitzgerald | Neutral |
| Mar-04-25 | Downgrade | Needham | Buy → Hold |
| Mar-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-03-25 | Downgrade | Stifel | Buy → Hold |
| Feb-10-25 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-10-25 | Downgrade | Citigroup | Buy → Neutral |
| Feb-10-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-10-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-10-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-10-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-10-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| May-18-23 | Initiated | Canaccord Genuity | Buy |
| Apr-13-23 | Initiated | Robert W. Baird | Outperform |
| Dec-14-22 | Initiated | Stifel | Buy |
| Dec-07-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Jul-20-22 | Initiated | SVB Leerink | Outperform |
| May-25-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-21 | Initiated | H.C. Wainwright | Buy |
| Apr-20-21 | Initiated | BTIG Research | Buy |
| Apr-05-21 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Cowen | Outperform |
| Jun-29-20 | Initiated | Needham | Buy |
| Jun-29-20 | Initiated | Piper Sandler | Overweight |
View All
Pliant Therapeutics Inc Stock (PLRX) Latest News
What drives Pliant Therapeutics Inc stock priceCapital Gains Strategies & Access Advanced Stock Screening Tools - earlytimes.in
Wall Street analysts’ outlook for Pliant Therapeutics Inc (PLRX) - Setenews
Total debt per share of Pliant Therapeutics, Inc. – SWB:9PT - TradingView
Pliant Therapeutics, Inc. (PLRX) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
What analysts say about Pliant Therapeutics Inc stockPrice Momentum Alerts & Small Capital Wealth Plans - earlytimes.in
Is Pliant Therapeutics Inc a good long term investmentFibonacci Extensions & Small Budget Trading Plans - earlytimes.in
Why Pliant Therapeutics Inc. (9PT) stock benefits from AI revolutionWeekly Loss Report & Accurate Intraday Trading Signals - newser.com
Can Pliant Therapeutics Inc. (9PT) stock double in coming yearsGold Moves & Safe Capital Allocation Plans - newser.com
Why Pliant Therapeutics Inc. stock is in analyst buy zone2025 Price Targets & Low Drawdown Investment Strategies - newser.com
How rising interest rates impact Pliant Therapeutics Inc. stockJuly 2025 Weekly Recap & Fast Entry High Yield Stock Tips - newser.com
Pliant Therapeutics Inc (PLRX) expanding its growth trajectory ahead - Setenews
Why global investors buy Pliant Therapeutics Inc. (9PT) stock2025 Geopolitical Influence & Free Real-Time Volume Trigger Notifications - newser.com
What high frequency data says about Pliant Therapeutics Inc.July 2025 News Drivers & Risk Adjusted Buy/Sell Alerts - newser.com
Why Pliant Therapeutics Inc. (9PT) stock could be top winnerMarket Performance Report & Free Real-Time Volume Trigger Notifications - newser.com
Does Pliant Therapeutics Inc. show high probability of reboundMarket Performance Report & Free Accurate Trade Setup Notifications - newser.com
Is Pliant Therapeutics Inc. stock near bottom after decline2025 Stock Rankings & Community Consensus Stock Picks - newser.com
Can Pliant Therapeutics Inc. stock maintain operating margins2025 Year in Review & Real-Time Stock Price Movement Reports - newser.com
Heatmap analysis for Pliant Therapeutics Inc. and competitors2025 Volume Leaders & Community Verified Watchlist Alerts - newser.com
Chart overlay techniques for tracking Pliant Therapeutics Inc.Weekly Trend Recap & Real-Time Stock Entry Alerts - newser.com
Is Pliant Therapeutics Inc. stock a safe buy before earningsWeekly Trading Summary & Expert Approved Trade Ideas - Fundação Cultural do Pará
How analysts rate Pliant Therapeutics Inc. stock todayTrade Risk Summary & AI Powered Buy and Sell Recommendations - Fundação Cultural do Pará
Will Pliant Therapeutics Inc. stock deliver shareholder valueQuarterly Portfolio Report & AI Based Trade Execution Alerts - Fundação Cultural do Pará
Why Pliant Therapeutics Inc. stock is popular among millennialsLayoff News & High Return Stock Watch Alerts - Fundação Cultural do Pará
Are Smart Investors Making the Right Decision? Pliant Therapeutics Inc (PLRX) - Setenews
Pliant Therapeutics Inc Stock (PLRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
1.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):